🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lonza Group AG (SWX:LONN)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
666.60
+3.60 (0.54%)
Nov 18, 2026, 5:31 PM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

The long-term model targets 10%-13% average growth, with expanding margins and ROIC; capacity projects and continued ADC investment support growth. The Merck KGaA deal adds U.S. capacity, while Vacaville is expected to reach up to CHF 2bn revenue in H1 2030.

James Vane-Tempest
Analyst, Jefferies

Good afternoon, everybody. Welcome to this afternoon session. My name is James Vane-Tempest. I cover the European pharma services sector. Delighted to be here with Lonza, the leading CDMO globally, and I have the CEO, Wolfgang Wienand, who will give a presentation. There is time at the end, some Q&A. With that, I hand over to Wolfgang. Thank you.

Wolfgang Wienand
CEO, Lonza

Yeah, thank you. Thank you very much, James, and thank you all for joining. Looking forward to talk about Lonza, our equity story, and in the end, take great questions, I would hope. With time being limited, let's immediately dive into our story, which is Lonza being a structural growth compounder with a pretty, I believe, attractive financial model. Before we actually talk, take a quick look at this disclaimer, take note, and feel bound to it. With that, the agenda is the Lonza engine delivers. Kind of me looking back, having joined the company on the 1st of July 2024, and kind of reporting back to you based on the promises that I myself and the company made to you at our investor update in December 2024.

Two years, 2.5 years looking back, and then building on that, why Lonza actually is such a strong financial model, a structural growth compounder. In the end, a few minutes, a few slides on the most recent M&A activities at Lonza, us signing a deal, not yet closing, signing a deal to acquire the Merck KGaA CDMO manufacturing network in the U.S. and then some time for us to talk. The Lonza strategy introduced to you in 2024 is built on six strategic imperatives. First one being, we focus on our pure play CDMO business, which led to quite significant consequences. Us selling our CHI business, a deal that we signed in March of this year, and expect to close by year-end at a valuation of CHF 1.6 billion-CHF 1.7 billion.

We went across high-value innovative modalities, so Lonza will continue to be a multi-modality CDMO and will continue to invest into future modalities to support mid and long-term growth. We differentiate through the Lonza engine. I will speak to that in a bit. We build a resilient and competitive global infrastructure. What I mean with that, I will talk about as well. We allocate capital with discipline at high returns, something that you probably care about. In the end, we compound value through resilient and repeatable, profitable, above-market growth. The Lonza engine. I actually won't take you through all of those things. I will leave it for you to read through. Just point at some things.

First of all, we spend time on thinking about what actually made Lonza the market leader in the space, what made us special in the past, and what gives us reasons to believe, to continue to be special, and to offer something to our clients for which they are actually willing to pay attractive prices and providing for attractive financial returns, considering the value that we provide to them. First of all is five pistons, high-performance teams, a leading scientific, technological, digital ecosystem, unparalleled customer partnerships, end-to-end execution, excellence, and plug-and-play investment and integration capabilities. I would actually like to point at two things. High-performance teams. Actually, three things. High-performance teams. We actually underwent a very significant change in the operating model towards how I believed a manufacturing company should be organized.

That was actually leading two of my top 300 leaders, almost none of them sitting on the same chair anymore, introduced 1st of April 2025 . And the company, the people actually impressed me a lot at that time because they did not only appreciate the change, but they made it work at a pace and also at a professional level, which I didn't see before. Since April 2025, we are operating in a new operating model, which helped us to deliver strong financial performance. The second one is unparalleled customer partnerships. Also here, we saw from an industry-leading Net Promoter Score an uptake, which I didn't expect at the time, so it actually doubled for big pharma companies and improved by 50% for small biotechs. Quite an amazing progression at the time.

While I wouldn't attribute all of it to our changes in the operating model, I would still think that this contributed. The last point of evidence for this Lonza engine being special and going to continue to help us to support our clients for their most important value creation questions is that going for, I mean, kind of new molecules coming into the company, 70% of them are based on integrated services, us providing not only drug substances or drug product, but actually combined services. That's the Lonza engine and what we did and what we achieved together along those criteria. Briefly on the new operating model. From divisions which actually have been managed almost completely separately, we converged to a more integrated operating model with three new business platforms: Advanced Synthesis, Integrated Biologics, Specialized Modalities. We also cleaned up portfolio and sold a number of businesses.

The biggest one, of course, CHI, including Capsules & Health Ingredients, and this is going to close by year-end. We also sold and gave away some smaller assets so that we can now actually claim that we are a pure play CDMO, and all my attention, all our attention going into that space where we actually have reasons to believe to really create superior value and where our true strength as a company lies. This all, of course, should translate into financial performance, and it actually did. Just as a reminder for those of you who actually follow us, if I look back at 2024, 2025, and what we expect for 2026, we actually have guided strong outlooks.

Always met them, and actually raised them during the year in 2025 and also in 2026, and have been able to significantly grow the company and to, at the same time, significantly expand margin. A number of reasons to that. I won't go through all of them, but in the end, it is a strong combination of a high-performance team, of a clear organizational model with clearer accountabilities, and an ever-improving interaction of global functions and the business platforms as our operational units. The Lonza, a structural growth compounder. Kind of building up our commercial, our financial model, and to start with is for me to define the opportunity, the market opportunity. How do we do that to, in the end, derive and infer from that what we as Lonza, as a market leader in the space, believe to be able to achieve over time.

First of all, the underlying market itself is, of course, a very special one, a unique one, I would say. I mean, non-cyclical, continuously growing at 6%-7% over decades, right? That's probably a great place, and we all, in one way or the other, enjoy such strong, attractive fundamentals. Lonza, based on portfolio decisions made over time, we actually pick those segments where, again, we believe we can deploy our strength the best and for the benefit of our clients, and also create somewhat more growth because those market segments outgrow the underlying market. That's a plus, a plus of a growth increment of 1%-2%. Then there's the benefit that the CDMO business model as such brings to the efficiency of global pharmaceutical supply.

The business model itself has been invented by Lonza in the 1970s and then over the last three to four decades, further developed. In the end, it is a very strong economic model that helps clients to produce, manufacture, develop, and manufacture products in a much more efficient way. In our view, and I think time has told us now in the meantime, the CDMO model is not the flavor of the day. It's a fundamental, important contribution to the global product supply in pharmaceuticals. There are a number of reasons to that. I won't go through them all. We might touch upon them in the Q&A. But we see that this business model from shifting volumes from pharmaceutical captive capacity to CDMOs like Lonza adds an additional growth increment of 1%-2%. That all adds up to Lonza's addressable CDMO market, 8%-10%.

Then there's the Lonza engine, what makes us special, which of course needs to translate into something. Otherwise, it's just words and a claim. Here we see that we, based on what makes us special, the Lonza engine, we can outgrow the market by 2%-3%. All of this adding up to what we actually have defined as our top-line ambitions on average over time of 10%-13% as the market opportunity for Lonza. Now the question is, what do we offer and what makes Lonza special in this arena? We actually tried to break it down, and we did so into three important ingredients for the value creation, for the value proposition of Lonza towards clients. First of all, it's of course about science, technology, and putting intelligence to data. It is about the operating system.

I mean, how we translate innovation, how we translate concepts into tangible products, and in the end, the infrastructure that we need to actually do that. The Lonza science, technology, intelligence is applicable across modalities. We are multi-modality manufacturing company, and we actually focus on the most difficult to make molecules. We codify that knowledge in our Lonza Operating System, which then is how we operate our assets on a global scale in a global risk-diversified, resilient, and competitive network. Talking about infrastructure, with growth of 10%-13% on average over time every year, we need to continuously feed the beast, right? Add capacity so that we don't run out of steam, right? In order to do that, we actually need to be very mindful not to miss the bus.

With lead times of, let's say, large-scale capacities of three to five years, a planning horizon of five years is actually dangerous, right? You need to look beyond in order to know precisely when you need to add the next increment of capacity so that you can actually deliver growth further out. That is what we do in a very structured, mindful way that materializes in a currently active CapEx project portfolio of 25 projects across the world. Value of that portfolio is CHF 8 billion, 90% into commercial mixed assets, which is the highest profitability assets, of course, across modalities. The expected return on invested capital, which for us is the ultimate financial measure of success, the expected ROIC of all those projects is between 30% and 40% at peak. Then there's this special thing, the Lonza Operating System. It looks complex.

It's supposed to look complex, right? Because it is complex. In the end, what we are offering to our customers is a kind of a combination of all relevant services. Analytical development, process development, up to manufacturing, across the life cycle of products, preclinical to commercial, across any scale, lab to large-scale manufacturing, within a consistent quality management system across the whole company, across One Lonza, across the globe. We actually do that for eight modalities, to take the breakthrough innovations of our clients and solve their, I mean, one of their two most important value questions. One is efficacy, of course. The drug needs to work, right? That's not our topic, that's theirs. But the second equally important value question for them is manufacturability. These are the problems that we solve for our clients.

In a sense, of course, we later on want to and need to and actually do provide a capacity to really also capture the value for Lonza. But if you think about it, we are not, at least at Lonza, we are not solving a capacity problem. We are not solving a procurement problem. We are solving a key value question, being manufacturability. We do that at any phase, any scale, across modalities, across the globe. A brief snapshot of our science and technology and intelligence landscape, where we actually offer our clients a leading IP portfolio across a number of key technologies. The Lonza GS system is actually the most prominent cell line system in biologics in the industry, having brought more than 100 drugs to market using our CHO cell line, for example.

We continue to invest into it to make it more stable, more productive, faster, and that also leads to faster services when it comes, for example, to taking a breakthrough innovation from DNA to IND within now six months. We do have differentiating technologies protected in terms of linkers, in terms of payloads, other things, that in the end leads to us being able to exactly provide solutions rather than only capacity. This all, of course, translated into a certain financial performance. Quickly take you through that. Looking back to 2019, we actually have seen the company grow at low teens. EBITDA margin actually remained flat, but we have been able to add CHF 2.5 billion since 2019. The interesting and, I think, exciting thing about the business model is it's highly resilient.

It is about risk diversification. The company Lonza, others, I guess, as well, in the CDMO space, went through all those external shocks like COVID-19, Ukraine war, biotech funding downturn, U.S. tariffs, Iran war, without anything happening to our business. If anything, financially positive because Lonza contributed to the supply of the Moderna COVID vaccine in 2021. We have been able to accelerate growth to a CAGR of 16%-17%, and over two years, have been able to elevate our profitability by 4 percentage points since 2024. ROIC goes up and also cash generation goes up. There is more to come. We are actually transforming our company also from a cultural perspective towards a higher operational intensity and to a higher competitive toughness along those five things.

Going forward, we will continue to significantly grow and even more so expand our margins, cash flow generation, and ROIC. This translates into what I call the organic growth model of Lonza, which is how we talk with you and talk to you about what you can expect from us going forward. It is not a guidance, it is more a model, it is a system, right? Here we see sales growth, low teens, organic CER sales growth on average over time, at expanding margins with our ambition midterm being to elevate our core EBITDA margin to the high 30s, which then through higher translation of EBITDA into free cash flow, provides for the cash that we need to invest into growth.

The investment into growth to be able to deliver the top line growth within that model will be between mid to high teens percentages of sales and high returns. Our ambition, and we will deliver that, mid to long term is to elevate our ROIC to 2-3x WACC 2026. What we are looking at here is a structural growth compounder because we are able to continue to provide opportunities into which we can invest our cash generated at the same or higher returns than before. This is compounding in the end. That means cash funds growth creates more cash, repeat. That is the Lonza organic growth model and how we think about our future.

So briefly on the acquisition that we just a few weeks ago announced in terms of signing, Merck KGaA and Lonza agreed to, for Merck to sell their U.S. CDMO manufacturing network of five sites altogether, St. Louis, Madison, Verona in Wisconsin, Carlsbad, and Indianapolis. This is about bioconjugation capacity, so serving ADCs. This is about payload linker manufacturing, serving ADCs. It is about viral vector manufacturing, drug substance, drug products in Carlsbad, and about LNP formulation and aseptic finished capacities. I would say actually almost a perfect match to our strategic ambitions and helping us to strengthen our footprint in the U.S., which is a key market for Lonza and has been a strategic imperative anyway.

And it helps us to, rather than having to invest ourselves with all the risks attached to that, all the time horizon attached to that, to immediately have available high-value capacity in a market where we as Lonza provide high value and are able to actually help our clients and turn that into very attractive opportunities. So kind of financial terms around that acquisition, which in my view is a true win-win for both the seller, Merck, and also clearly for Lonza. So in 2028, we expect this business to contribute ±CHF 250 million in terms of revenue at a actually very low EBITDA margin. But we at Lonza will be able to actually elevate that business based on the existing empty capacity to peak sales level, which will be very attractive for Lonza by the mid-2030s.

And at the same time, through different means, increasing utilization, having probably a stronger go-to-market organization, being the market leader in the CDMO space to the then current group profitability level in the mid-2030s. Enterprise valuation was between low and mid triple-digit million Swiss francs. Expected closing mid-2027. And, what does it do to our organic growth model? I mean, just formally, mathematically, in terms of growth, it is slightly accretive. Doesn't really move the needle though, based on the small revenue number compared to the overall sales aggregate of Lonza. In terms of margin, it obviously is dilutive, but again, doesn't move the needle really, which means, first of all, as soon as we have reached mid-2030s, it will be significantly ROIC accretive to the group. There is no change to Lonza's outlook for 2026, of course, closing in 2027 only.

But there is also no change to the Lonza organic growth model that I have been just talking about, and no change to our midterm financial ambitions when it comes to profitability. Strategic rationale, we unlock growth opportunities across One Lonza. It is actually across two modalities, right? ADCs and viral vector, and three modalities, actually drug product as well. We create capacity or get access to capacity exactly where we would otherwise had to build it, which is in the U.S., and also acquire an attractive development pipeline from Merck. And with regard to our Cell & Gene business, we add attractive capacity in the U.S. for viral vectors with a focus on lentivirus and combined offering of drug substance and drug products.

So far, Lonza only had one viral vector manufacturing site in Houston, and adding another high-quality site will actually create the critical scale for us as Lonza in that attractive space. With that, I want to leave you with five key messages. Today, we have delivered on all our commitments made in December 2024. We operate in a structurally attractive market that supports our long-term opportunity. We are the innovation-to-launch integrator that offers highly differentiated and uniquely comprehensive CDMO services, so we solve a key value question, manufacturability. We do not solve, first and foremost, a procurement question. We deliver on our organic growth model, making Lonza an attractive structural growth compounder, and we will continue to execute disciplined and selective M&A in line with the One Lonza strategy, which then accelerates our organic growth model.

With that, I would close the presentation and over to James, and we will be happy to answer questions of yours, if any. Thank you so much.

James Vane-Tempest
Analyst, Jefferies

Thank you, Wolfgang. I think we have got about three minutes, maybe, just a couple, a few questions if I can. Maybe with a high-level one. You mentioned you are targeting 2-3x WACC for your ROIC over time. Many generalists are looking at the capital intensity of the business in this framework. How should we think about the outcomes and priorities that would determine the lower and the upper end of that construct?

Wolfgang Wienand
CEO, Lonza

Yeah, it is not so much that I would have a target state in mind, one of which actually leads to the lower end and the other one to the upper end. For me, it is more a trajectory over time. We see a pathway actually to this range of 2-3x WACC, and rather than I would see the organic growth model rather as something which rolls forward, right? With us applying that and delivering upon that model at ever-increasing profitability, that will just lead to us elevating step by step towards that target level of 2-3x WACC.

James Vane-Tempest
Analyst, Jefferies

Thank you. Thinking about the potential upside from ADCs, I think you mentioned you are fully utilized, but you made a number of investments to expand capacity. How should we think about the timing of new capacity to sustain growth in this segment, given a strong first half?

Wolfgang Wienand
CEO, Lonza

You relate, I mean, specifically to the Merck capacities in the U.S. or more general?

James Vane-Tempest
Analyst, Jefferies

More organic outside of the Merck. I mean, in addition, to be honest.

Wolfgang Wienand
CEO, Lonza

Yeah. Actually, we continue to invest into ADC capacities also in Visp, and announced another one just recently into payload linker. That is in the making in a certain way. What we always try to do is not to run out of steam so that we connect, that we actually need to kind of reject growth opportunities. We do have capacity available and continue to add. With the Merck business, we are doing it in one important big step in a place where we actually would have to build otherwise ourselves.

James Vane-Tempest
Analyst, Jefferies

Thank you. Then final one for me, I think in the time we have. A lot of material covered in the presentation, but I guess you also hosted a recent investor site visit at Vacaville where you raised those kind of longer-term ambitions. Perhaps for those less familiar with that site, can you give a sense of when these new projects are expected to ramp up and contribute to those higher profitability and returns?

Wolfgang Wienand
CEO, Lonza

Yeah. Thank you, James. Indeed, first and foremost, while it wasn't me to make that acquisition at the time, I think it's a great addition to One Lonza, and probably one site of a kind which you don't find many times, if at all, in the world. It adds significant capacity, 332,000 cu m fermentation biological capacity. I mean, high-quality asset, highly qualified team, and we are currently investing into the flexibility, into the CDMO capability of the site, which translates into, based on the business which we still have with Roche, and which we already acquired and are currently bringing to the site, leads to considering shutdown times in the time between 2024, 2025, 2025 and 2028 to kind of, I'm wobbling, of course, but sales of around CHF 0.5 billion.

The contracts and the products that we are actually bringing into the site right now are already sufficient to not only fully compensate the outgoing Roche volumes, but to also then drive growth starting in 2029. So right now, the Vacaville site is actually growth-dilutive , and it's also kind of in terms of margin not contributing yet. But the true value creation starts in 2029. We expect the site to be fully utilized, I mean, humming in a way, in the first half of 2030, and then delivering up to CHF 2 billion in terms of revenue at very attractive margins and very attractive returns, elevating, of course, at that scale, and the whole group in terms of both KPIs.

James Vane-Tempest
Analyst, Jefferies

Wonderful.

Wolfgang Wienand
CEO, Lonza

Great asset to have, I can tell.

James Vane-Tempest
Analyst, Jefferies

Thank you, Wolfgang. We're out of time. Wolfgang Wienand from Lonza, thank you very much.